vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and CVD EQUIPMENT CORP (CVV). Click either name above to swap in a different company.
Azenta, Inc. is the larger business by last-quarter revenue ($148.6M vs $5.0M, roughly 30.0× CVD EQUIPMENT CORP). Azenta, Inc. runs the higher net margin — -10.4% vs -25.6%, a 15.2% gap on every dollar of revenue. On growth, Azenta, Inc. posted the faster year-over-year revenue change (0.8% vs -33.2%). Azenta, Inc. produced more free cash flow last quarter ($14.7M vs $396.0K). Over the past eight quarters, Azenta, Inc.'s revenue compounded faster (4.4% CAGR vs 0.3%).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
CVD Equipment Corp designs, manufactures and supplies custom chemical vapor deposition systems, thermal processing equipment and related process control solutions. Its offerings cater to semiconductor manufacturing, renewable energy, aerospace, and advanced materials research segments, serving commercial and academic customers globally.
AZTA vs CVV — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $5.0M |
| Net Profit | $-15.4M | $-1.3M |
| Gross Margin | 42.9% | 22.2% |
| Operating Margin | -4.9% | -27.2% |
| Net Margin | -10.4% | -25.6% |
| Revenue YoY | 0.8% | -33.2% |
| Net Profit YoY | -15.7% | -1060.6% |
| EPS (diluted) | $-0.34 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.6M | $5.0M | ||
| Q3 25 | $159.2M | $7.4M | ||
| Q2 25 | $143.9M | $5.1M | ||
| Q1 25 | $143.3M | $8.3M | ||
| Q4 24 | $147.4M | $7.4M | ||
| Q3 24 | $150.6M | $8.2M | ||
| Q2 24 | $144.3M | $6.3M | ||
| Q1 24 | $136.4M | $4.9M |
| Q4 25 | $-15.4M | $-1.3M | ||
| Q3 25 | $50.9M | $384.0K | ||
| Q2 25 | $-48.0M | $-1.1M | ||
| Q1 25 | $-47.7M | $360.0K | ||
| Q4 24 | $-11.0M | $132.0K | ||
| Q3 24 | $-6.6M | $203.0K | ||
| Q2 24 | $-6.6M | $-761.0K | ||
| Q1 24 | $-137.4M | $-1.5M |
| Q4 25 | 42.9% | 22.2% | ||
| Q3 25 | 45.4% | 32.7% | ||
| Q2 25 | 46.2% | 21.0% | ||
| Q1 25 | 43.8% | 32.4% | ||
| Q4 24 | 46.7% | 26.3% | ||
| Q3 24 | 45.5% | 21.5% | ||
| Q2 24 | 44.8% | 24.3% | ||
| Q1 24 | 43.8% | 16.2% |
| Q4 25 | -4.9% | -27.2% | ||
| Q3 25 | 1.2% | 4.2% | ||
| Q2 25 | -1.3% | -22.3% | ||
| Q1 25 | -12.7% | 3.2% | ||
| Q4 24 | -5.9% | 0.4% | ||
| Q3 24 | -3.1% | 0.9% | ||
| Q2 24 | -4.9% | -14.2% | ||
| Q1 24 | -18.1% | -33.0% |
| Q4 25 | -10.4% | -25.6% | ||
| Q3 25 | 32.0% | 5.2% | ||
| Q2 25 | -33.4% | -20.8% | ||
| Q1 25 | -33.3% | 4.3% | ||
| Q4 24 | -7.5% | 1.8% | ||
| Q3 24 | -4.4% | 2.5% | ||
| Q2 24 | -4.5% | -12.0% | ||
| Q1 24 | -100.8% | -29.9% |
| Q4 25 | $-0.34 | $-0.19 | ||
| Q3 25 | $1.12 | $0.06 | ||
| Q2 25 | $-1.05 | $-0.15 | ||
| Q1 25 | $-1.04 | $0.05 | ||
| Q4 24 | $-0.25 | $0.02 | ||
| Q3 24 | $-0.25 | $0.03 | ||
| Q2 24 | $-0.12 | $-0.11 | ||
| Q1 24 | $-2.48 | $-0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $8.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.7B | $24.7M |
| Total Assets | $2.1B | $27.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $336.6M | $8.7M | ||
| Q3 25 | $279.8M | $8.4M | ||
| Q2 25 | $270.0M | $7.0M | ||
| Q1 25 | $253.6M | $10.2M | ||
| Q4 24 | $377.5M | $12.6M | ||
| Q3 24 | $280.0M | $10.0M | ||
| Q2 24 | $336.5M | $10.0M | ||
| Q1 24 | $353.5M | $11.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $268.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.7B | $24.7M | ||
| Q3 25 | $1.7B | $25.8M | ||
| Q2 25 | $1.7B | $25.2M | ||
| Q1 25 | $1.7B | $26.0M | ||
| Q4 24 | $1.7B | $25.4M | ||
| Q3 24 | $1.8B | $25.0M | ||
| Q2 24 | $2.0B | $24.5M | ||
| Q1 24 | $2.2B | $25.0M |
| Q4 25 | $2.1B | $27.5M | ||
| Q3 25 | $2.1B | $29.8M | ||
| Q2 25 | $2.0B | $29.9M | ||
| Q1 25 | $2.0B | $31.1M | ||
| Q4 24 | $2.0B | $31.7M | ||
| Q3 24 | $2.1B | $31.8M | ||
| Q2 24 | $2.3B | $33.8M | ||
| Q1 24 | $2.6B | $35.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | $397.0K |
| Free Cash FlowOCF − Capex | $14.7M | $396.0K |
| FCF MarginFCF / Revenue | 9.9% | 8.0% |
| Capex IntensityCapex / Revenue | 4.2% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.8M | $397.0K | ||
| Q3 25 | $2.2M | $1.4M | ||
| Q2 25 | $25.8M | $-3.2M | ||
| Q1 25 | $14.4M | $-2.3M | ||
| Q4 24 | $29.8M | $2.3M | ||
| Q3 24 | $17.7M | $32.0K | ||
| Q2 24 | $9.8M | $-1.7M | ||
| Q1 24 | $8.7M | $-2.0M |
| Q4 25 | $14.7M | $396.0K | ||
| Q3 25 | $-5.7M | — | ||
| Q2 25 | $15.0M | $-3.2M | ||
| Q1 25 | $7.0M | $-2.3M | ||
| Q4 24 | $22.0M | $2.1M | ||
| Q3 24 | $8.3M | $-5.0K | ||
| Q2 24 | $1.3M | $-1.8M | ||
| Q1 24 | $428.0K | $-2.1M |
| Q4 25 | 9.9% | 8.0% | ||
| Q3 25 | -3.6% | — | ||
| Q2 25 | 10.4% | -62.1% | ||
| Q1 25 | 4.9% | -27.7% | ||
| Q4 24 | 15.0% | 28.8% | ||
| Q3 24 | 5.5% | -0.1% | ||
| Q2 24 | 0.9% | -29.0% | ||
| Q1 24 | 0.3% | -42.9% |
| Q4 25 | 4.2% | 0.0% | ||
| Q3 25 | 4.9% | 0.0% | ||
| Q2 25 | 7.5% | 0.1% | ||
| Q1 25 | 5.2% | 0.5% | ||
| Q4 24 | 5.3% | 1.5% | ||
| Q3 24 | 6.2% | 0.5% | ||
| Q2 24 | 5.9% | 1.8% | ||
| Q1 24 | 6.1% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | 0.04× | 3.53× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6.28× | ||
| Q4 24 | — | 17.05× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
CVV
| Transferred Over Time | $3.8M | 76% |
| Transferred At Point In Time | $1.2M | 24% |
